Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Summary Autologous CD19 CAR-T cell therapy shows promise for treating relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Studies Read More
Tags :Lymphoma
Education, Research & Positions
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma Summary Combining MCL-1 inhibition with CD37-directed CAR T-cell therapy shows promise for treating T-cell lymphoma. Read More
Education, Research & Positions
Author Correction: Allogeneic NK cells with a bispecific innate cell
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial Summary In a phase 1 trial, researchers explored the safety and efficacy of allogeneic natural killer (NK) cells Read More
Site Logo
Powered by AI
New Journal Citation Reports (JCR) 2025
All-Time Views
1 Million+ Views and Counting..!
Follow me on Linkedin for Latest Jobs and Scholarships
Subscribe Youtube
Celebrating 6 Years
Now, it has been 6 years since it was launched in late July 2018 and is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
Site Trust Score
Google Safe
Site Traffic
